The stock's fall snapped a two-day winning streak.

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...

It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 20% over the past three months. It seems that the market might have completely ...

Biogen looks reasonably attractive at current levels. Sentiment and expectations are extremely low, and I see the stock as a valuation re-rating candidate in the following quarters. And there is ...

Biogen Inc. closed $118.40 short of its 52-week high ($268.30), which the company achieved on January 3rd.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart ...